Sema4 was founded by world-renowned computational biologist Dr. Eric Schadt, who has extensive industry experience in generating drug candidates through advanced network modeling. Our team of 100+ PhD-level scientists are world-leading experts in big data, network modeling, systems biology, multiscale biotechnology, and genomics. Between them, they have published more than a thousand peer-reviewed publications in the last five years
We collect, standardize, normalize, structure, and abstract meaning from enormous amounts of multidimensional, large-scale data. From patient data from health systems to molecular data from our advanced sequencing tests, we have access to rich, highly secure data. By transforming these data into a common model that enables portability across health systems and using artificial intelligence (AI)-driven natural language processing (NLP) to process unstructured data, we generate enhanced, structured data that can be used to optimize patient health trajectories.
Analytics & Insights
Centrellis harnesses state-of-the-art AI algorithms we and others have developed to deliver substantial analytical horsepower that enables the construction and validation of advanced predictive models, including probabilistic causal network models. These models are capable of generating actionable insights that can inform decision-making across the drug discovery, development, and commercialization pipeline. We are fluent in how to deliver these insights and their benefits to the Biopharma industry.
Advanced Solutions, Services, and Support to Accelerate All Stages of the Drug Development Lifecycle
We have the tools and expertise to transform an ocean of raw data into powerful information. We can then convert this information into knowledge and, ultimately, a level of understanding that can help answer questions fundamental to the Biopharma industry. From models that can optimize the design of a phase III rare disease trial, to leveraging real-world evidence to enable development of digital trials, to key mechanistic insights regarding disease subtypes, we can generate the strategic answers to power your drug development pipeline and achieve better outcomes for patients.
- Characterization of patient journeys
- Post-market patient engagement
- Identification of new market opportunities
- Formulary decisions
- Clinical outcome analysis
A Trusted Partner to Biopharma
Sema4 has a proven track record of success in working with the Biopharma industry. Learn about some of our recent projects below.
Clinical Research Study Support
We are conducting a five-year collaborative study with Sanofi to provide new insights into the biological mechanisms and other factors implicated in asthma. The project is currently recruiting nearly 1,200 people with asthma. It will follow them to collect a range of data—from traditional clinical data to genomics, immunological, environmental, and sensor data from mobile devices—to enable sophisticated analysis and advanced network modeling of this complex disease.
For more information, see the press release we issued on this study.
Scientists from Sema4, Icahn School of Medicine at Mount Sinai, and Eli Lilly and Company recently published the results of a study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods. These findings could pave the way for streamlined drug discovery, particularly for diseases such as schizophrenia that have seen little therapeutic innovation.